GT
VRTX icon

Glenview Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Glenview Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Sell
6,751
-244
-3% -$108K 0.05% 193
2026
Q1 		$3.12M Sell
6,995
-10
-0.1% -$4.66K 0.05% 192
2025
Q4 		$3.18M Buy
7,005
+24
+0.3% +$10.3K 0.05% 189
2025
Q3 		$2.73M Sell
6,981
-95
-1% -$39.7K 0.04% 202
2025
Q2 		$3.15M Buy
7,076
+156
+2% +$71.9K 0.05% 187
2025
Q1 		$3.35M Buy
6,920
+30
+0.4% +$14K 0.07% 170
2024
Q4 		$2.77M Buy
6,890
+152
+2% +$70.5K 0.05% 184
2024
Q3 		$3.13M Sell
6,738
-12
-0.2% -$5.76K 0.06% 172
2024
Q2 		$3.16M Buy
6,750
+180
+3% +$78.1K 0.06% 166
2024
Q1 		$2.75M Buy
6,570
+180
+3% +$76.1K 0.06% 176
2023
Q4 		$2.6M Buy
6,390
+98
+2% +$36.2K 0.06% 173
2023
Q3 		$2.19M Hold
6,292
– – 0.06% 173
2023
Q2 		$2.21M Buy
6,292
+57
+0.9% +$19.2K 0.06% 170
2023
Q1 		$1.96M Sell
6,235
-155
-2% -$46.5K 0.06% 175
2022
Q4 		$1.85M Buy
6,390
+527
+9% +$161K 0.06% 170
2022
Q3 		$1.7M Buy
5,863
+684
+13% +$197K 0.06% 161
2022
Q2 		$1.46M Buy
5,179
+24
+0.5% +$6.42K 0.05% 170
2022
Q1 		$1.34M Buy
+5,155
New +$1.22M 0.04% 186
2021
Q4 		– Sell
-3,890
Closed -$705K – 431
2021
Q3 		$705K Buy
3,890
+1,915
+97% +$374K 0.03% 229
2021
Q2 		$398K Buy
+1,975
New +$413K 0.02% 305

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Glenview Trust's VRTX Position: Q2 2026 in Review

Glenview Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 3.5% in Q2 2026, selling an estimated $108K and leaving 6,751 shares worth $3.35M. The position accounts for 0.05% of the portfolio, ranked #193.

Glenview Trust first reported a position in VRTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $3.35M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Glenview Trust held 6,751 shares of Vertex Pharmaceuticals worth $3.35M as of Q2 2026.
  • Glenview Trust sold 244 Vertex Pharmaceuticals shares in Q2 2026, an estimated $108K.
  • Vertex Pharmaceuticals made up 0.05% of Glenview Trust's portfolio in Q2 2026, its #193 holding.
  • Glenview Trust first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Glenview Trust's Vertex Pharmaceuticals position peaked at $3.35M in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Glenview Trust's 13F filing for Q2 2026, filed 11 Aug 2026.